'Overwhelming' bleeding reduction with abelacimab versus rivaroxaban in AF leads to early halting of trial
USA: Abelacimab, a novel factor XI/XIa inhibitor being studied in the AZALEA-TIMI 71 trial, was shown to lower a composite of major and clinically relevant nonmajor bleeding versus rivaroxaban in atrial fibrillation (AF) patients at a moderate-to-high-risk-of stroke. The results were announced by the drug's manufacturer Anthos Therapeutics.
Abelacimab is a novel, highly selective, fully human monoclonal antibody with dual inhibitory activity against factor XI and its active form, factor XIa.
The AZALEA-TIMI 71 trial stopped early due to an unprecedented bleeding benefit for adults with AF. The company noted that abelacimab is also the first and only factor XI inhibitor to demonstrate an unprecedented reduction in major bleeding compared with a DOAC (direct oral anticoagulant).
"The study was stopped by the data monitoring committee after it met its primary endpoint, a composite of major and clinically relevant nonmajor bleeding, in participants taking abelacimab versus patients taking rivaroxaban (Xarelto, Janssen/Bayer), a factor X inhibitor and a leading standard-of-care DOAC," Anthos stated in a press release.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.